The Food and Drug Administration (FDA) announced steps the agency is taking the accelerate access to therapeutics for COVID-19. Through a cross-agency effort, the FDA is conducting expanded-use clinical trials for chloroquine, a drug already approved for malaria, lupus, and rheumatoid arthritis. It is the hope of the FDA that this medicine will show promising results in reducing the symptoms and preventing the spread of COVID-19.
Below are additional steps the FDA is taking to expand treatment access:
- A randomized controlled trial for remdesivir, a Gilead product, to assess the efficacy of the drug for COVID-19.
- Leveraging scientific information from clinical trials in China, Japan, South Korea, and Italy.
- Evaluating the whether therapies like gathering convalescent plasma and hyperimmune globulin from recovered patients can improve infected patient status.